At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 55 enrolled
Drug / intervention
Ruxolitinib 1.5% cream +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Safety and Efficacy Study of Ruxolitinib Cream Combined With Narrow-Band Ultraviolet B Phototherapy in Participants With Vitiligo
In Brief
A Phase 2 clinical trial evaluating Ruxolitinib 1.5% cream and NB-UVB phototherapy for Vitiligo. Completed, enrolled 55 participants across 13 sites in 2 countries.
Detailed Summary
The purpose of this study is to evaluate the efficacy and safety of Ruxolitinib cream with or without phototherapy in adolescent and adult participants with non-segmental vitiligo for whom vitiligo area (facial and nonfacial) does not exceed 10% body surface area (BSA).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsVitiligo
CountriesCanada, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2023202420252026
First PostedFeb 2022
Enrollment StartMay 2022
Primary CompletionDec 2023
TodayJul 2026
First PostedFeb 21, 2022
Enrollment StartMay 5, 2022
Primary CompletionDec 19, 2023
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 4.4 years ago
Interventions
Ruxolitinib 1.5% creamdrug
Ruxolitinib cream 1.5% applied twice a day (BID).
NB-UVB phototherapydevice
NB-UVB (311-312 nm) phototherapy is an established treatment modality for vitiligo. Starting dose will be 200 mJ/cm2 and dose may be increased by 10% at each visit